Los Angeles medical cannabis lawyers

August 14, 2018

$32,500 for Medical Cannabis? Are You High?

The company that produced the first ever cannabis-derived medicine to be approved for use by the U.S. Food & Drug medical cannabis Administration has revealed to investors the cost of the drug: $32,500 per year. This is reportedly on the low-end of original estimates between $30,000 and $60,000. Epidiolex, made with CBD and used to treat rare forms of childhood epilepsy, is said to be priced competitively with other epilepsy drugs on the market. This, however, is not other epilepsy drugs.

One of the reasons, among many, that marijuana has become so popular for medicinal use is that it is relatively inexpensive compared to other treatments, even without the help of insurance companies to cover the costs. Some markup by pharmaceutical companies is to be expected to cover testing, research, and ensure consistency and purity of the product. The disparity between cost and price in this instance seems specifically designed to prey on desperate families already prepared to pay top dollar to help their children. In fact, the price was set with the consultation of insurance companies, according to a Business Insider report.

April 30, 2018

It’s Time for NFL to Put Medical Marijuana in the Game

By Cannabis Law Group

The NFL, as with so many other professional and minor league sports teams, still ascribes to official federal line on marijuana, which is that as a Schedule I narcotic, it is highly addictive, dangerous and has no medicinal value. Of course, our cannabis lawyers in L.A. know that runs counter to the evidence and what dozens of states have thus far concluded. Given that NFL players are some of the most tenacious athletes – and take the hardest hits – they more than most might benefit from medicinal marijuana as an alternative to powerful and highly addictive opioid painkillers. But until the organization changes its stance, we’ll continue to have conflicts such as those seen with free agent Mike James. medical marijuana

James, a running back, injured his ankle during a football game in 2013. According to a CNN report, he was prescribed opioid painkillers. In short order (as so often happens) he became dependent on the pills. He became aware that an addiction was forming and wanted something safer to ease the pain.

After some research, he concluded marijuana was truly the best option – to ease the pain, end his addiction and maintain his physical prowess. James had some reservations about this decision, witnessing the way drug addiction in general harmed his family and his childhood communities. But, like a majority of Americans, he soon learned that cannabis does not belong in the same category as other street drugs at all, and decided to take the leap.

The NFL, unfortunately still takes a hard-line stance with marijuana use by players, who are drug-tested regularly. (Yet League officials see no problem whatsoever with players consuming dangerous opioid pain relievers.) CNN points to to a study from Drug and Alcohol Dependence, in which over half of ex-NFL players surveyed said they used opioids, with 71 percent of them admitting they misused them. Support for prescription painkillers continues, despite many leaders – President Trump included – have declared opioid addiction an epidemic. When it comes to medical marijuana, though, which can be a safe, effective, and non-habit forming treatment under proper medical guidance, this is where NFL leaders choose their line in the sand.

April 2, 2018

Medical Marijuana Study in Israel Lights Way for Cancer Treatments

By Cannabis Law Group

Here in California, we have more than 20 years of anecdotal evidence of the ways medical marijuana can be used to treat a variety of ailments. Thanks to the Compassionate Use Act of 1996, patients have been reaping the benefits of cannabis for everything from glaucoma to anxiety and chronic pain. Unfortunately, the research that would help independently establish these things has largely been stifled in the U.S., owing largely to the federal policy that classifies marijuana as a Schedule I narcotic. Meanwhile, as reported by U.S. News & World Report, Israel has become a leader in marijuana research – and one of the latest findings of Israeli researchers underscores the medicinal properties of marijuana for cancer patients.

Published in the European Journal of Internal Medicine, the study analyzes the effects of cannabis on symptoms related to cancer and cancer treatments. These include nausea, vomiting, headaches, weakness, pain, and more. According to the study, 1,046 out of 1,742 reported success in overcoming these symptoms after six months. This total did not include participants who passed away, switched cannabis providers, or did not respond to questionnaires. The study looked mostly at patients who were at an advanced stage of cancer and on average 60-years-old. These factors meant a quarter of patients died before the study was over, but even many of those patients reported having the pain of their condition eased by cannabis.